RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold

Trial Profile

RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms RESTORE-II
  • Sponsors REVA Medical
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
    • 28 Jan 2014 According to ClinicalTrials.gov record planned end date changed from 1 Aug 2018 to 1 Sep 2018.
    • 13 Jan 2014 Data will be presented at the Paris Course on Revascularization (EuroPCR), according to a REVA Medical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top